Themis MedicareNSE:THEMISMED -2.64%74 EBITDA Margin % is 18.76% as of Mar. 2026, which is 4% above its 10-year median of 18.03. GuruFocus rates NSE:THEMISMED with a GF Score™ of 74/100 and a GF Value™ of ₹149.53 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 953 Drug Manufacturers companies, Themis Medicare ranks worse than 63.8% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Themis Medicare's EBITDA for the
three
months ended in Mar. 2026 was ₹144 Mil. Themis Medicare's Revenue for the
three
months ended in Mar. 2026 was ₹765 Mil. Therefore, Themis Medicare's EBITDA margin for the quarter that ended in Mar. 2026 was 18.76%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Themis Medicare EBITDA Margin % Related Terms
Themis Medicare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Themis Medicare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THEMISMED vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Themis Medicare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Themis Medicare EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Themis Medicare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Themis Medicare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Themis Medicare (NSE:THEMISMED) has a EBITDA Margin % of 18.76% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Themis Medicare and its competitors. This is near median its historical median of 18.03. Over the past decade, Themis Medicare's EBITDA Margin % has ranged from 3.18 to 28.43. According to the industry distribution chart, Themis Medicare ranks #608 out of 953 companies in the Drug Manufacturers industry, placing it in the top 63.8%.
Is Themis Medicare's EBITDA Margin % too high?
Themis Medicare's current EBITDA Margin % of 18.76% is near median its 10-year median of 18.03. Over the past 10 years, this metric has ranged from a low of 3.18 to a high of 28.43. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Themis Medicare's value of 18.76% is 49.6% above this industry median. Based on the distribution chart, Themis Medicare ranks #608 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Themis Medicare has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Themis Medicare's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Themis Medicare ranks #608 out of 953 companies for EBITDA Margin %. This places Themis Medicare in the lower half of its industry. The industry median EBITDA Margin % is 12.54. Themis Medicare's value of 18.76% is 49.6% above this benchmark. Historically, Themis Medicare's own EBITDA Margin % has ranged from 3.18 to 28.43 over the past decade. While the company's 10-year median is 18.03 vs. the industry median of 12.54, Themis Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Themis Medicare's current EBITDA Margin % of 18.76% is 49.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Themis Medicare and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Themis Medicare's current EBITDA Margin % is 18.76%, which is near median its own 10-year median of 18.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Themis Medicare stock overvalued right now?
Based on GuruFocus' analysis, Themis Medicare (NSE:THEMISMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹149.53, compared to a current price of ₹109.55 — trading 26.7% below its estimated fair value. The current EBITDA Margin % is 18.76%, which is near median its 10-year median of 18.03 and 49.6% above the Drug Manufacturers industry median of 12.54. Themis Medicare's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Themis Medicare (NSE:THEMISMED), the current EBITDA Margin % is 18.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Themis Medicare (NSE:THEMISMED) Overvalued in 2026?
Based on GuruFocus' analysis, Themis Medicare stock appears to be undervalued.
The current stock price of ₹109.55 is trading 26.7% below its estimated GF Value™ of ₹149.53.
GuruFocus considers Themis Medicare to be Modestly Undervalued.
Key valuation signals for NSE:THEMISMED:
EBITDA Margin %: 18.76% (near median its 10-year median of 18.03)
GF Value™: ₹149.53 vs. price of ₹109.55 (26.7% below fair value)
Industry Position: 49.6% above the Drug Manufacturers median (#608 of 953)
No single metric tells the full story. See the NSE:THEMISMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Themis Medicare Ltd is an Indian based company engaged in the manufacturing and marketing of pharmaceutical products. The Company operates only in one business segment which is Pharmaceuticals. Geographically, it derives a majority of revenue from India and also has a presence in the international market. Its product categories include Anti Malarial, CCD products, Nutritional Gummies, and Candy and Other Products such as OD-LM, Dexem, Medzol and Tazowin.
74GF Score
Get the complete analysis for NSE:THEMISMED
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THEMISMED has been successfully added to your 
